Larimar Cash Reserves Reach $136.9M, Advancing FDA Registration
As of December 31, 2025, the company had cash, cash equivalents and marketable securities totaling $136.9M together with net proceeds of $107.6M from the February 2026 public offering. The company has projected cash runway into 2Q27. "This is an exciting and pivotal time for Larimar as we continue advancing nomlabofusp toward registration. Receiving Breakthrough Therapy Designation from the FDA highlights both the significant unmet needs in Friedreich's ataxia and the potential of nomlabofusp to address the underlying frataxin deficiency that causes the disabilities experienced by people with FA," said CEO Carole Ben-Maimon. "Importantly, our ongoing engagement with the FDA reinforces our registrational path, and we remain on track to submit our Biologics License Application seeking accelerated approval in June 2026. In Q2 of this year, we expect to report topline data from our open label study, as well as initiate screening in our global confirmatory Phase 3 study. With a strengthened balance sheet following our recent financing and an extended cash runway into 2Q27, we are strongly positioned to execute on our registrational milestones over the next 12 months. Nomlabofusp has the potential to become the first disease-modifying therapy for FA, and we are committed to delivering it as rapidly as possible to the FA community who continues to face significant unmet medical need."
